POLYPID LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.752 USD | -1.12% |
|
+8.01% | +25.07% |
| 02-14 | Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024 | |
| 02-14 | PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 22.8M 31.16M |
|---|---|---|---|---|---|
| Net income 2024 * | -25M -34.17M | Net income 2025 * | -24M -32.81M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.32
x | P/E ratio 2025 * |
-2.01
x | Employees | 61 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on PolyPid Ltd.
More recommendations
More press releases
| 1 day | -1.12% | ||
| 1 week | +8.01% | ||
| Current month | +3.32% | ||
| 1 month | -1.81% | ||
| 3 months | -27.44% | ||
| 6 months | +28.31% | ||
| Current year | +25.07% |
1 week
4.40
4.90
1 month
4.205.50
Current year
4.109.20
1 year
3.5713.50
3 years
3.57289.20
5 years
3.57583.50
10 years
3.57583.50
| Managers | Title | Age | Since |
|---|---|---|---|
Dikla Akselbrad
CEO | Chief Executive Officer | 50 | 14-06-30 |
Jonny Missulawin
DFI | Director of Finance/CFO | 37 | - |
| Chief Tech/Sci/R&D Officer | - | 16-02-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Stein
BRD | Director/Board Member | 73 | 20-02-29 |
Itzhak Krinsky
BRD | Director/Board Member | 71 | 18-11-30 |
| Director/Board Member | 82 | 08-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.752 | -1.12% | 2,321 |
| 24-04-25 | 4.806 | +5.47% | 1,523 |
| 24-04-24 | 4.557 | +1.62% | 885 |
| 24-04-23 | 4.484 | +1.34% | 905 |
| 24-04-22 | 4.425 | +0.57% | 3,559 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm
More quotes
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.752
USD
Average target price
12.33
USD
Spread / Average Target
+159.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.07% | 22.8M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PYPD Stock
